STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Location
Title and abstract	1	(a) Indicate the study's design with a commonly used term in	
		the title or the abstract	title
		(b) Provide in the abstract an informative and balanced	a la adma a d
		summary of what was done and what was found	abstract
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the	
		investigation being reported	background
Objectives	3	State specific objectives, including any prespecified	background,
		hypotheses	paragraph 3
Methods			
Study design	4	Present key elements of study design early in the paper	methods, para 1
Setting	5	Describe the setting, locations, and relevant dates, including	***
		periods of recruitment, exposure, follow-up, and data	methods, para 1-4
		collection	
Participants	6	(a) Give the eligibility criteria, and the sources and methods	
		of selection of participants. Describe methods of follow-up	methods, para 1-2
		(b) For matched studies, give matching criteria and number of	~ /o
		exposed and unexposed	n/a
Variables	7	Clearly define all outcomes, exposures, predictors, potential	methods, para 2-6;
		confounders, and effect modifiers. Give diagnostic criteria, if	results tables
		applicable	results tables
Data sources/	8*	For each variable of interest, give sources of data and details	
measurement		of methods of assessment (measurement). Describe	methods, para 2
		comparability of assessment methods if there is more than	
		one group	
Bias	9	Describe any efforts to address potential sources of bias	discussion
Study size	10	Explain how the study size was arrived at	convenience sample - n/a
Quantitative variables	11	Explain how quantitative variables were handled in the	II/ U
		analyses. If applicable, describe which groupings were chosen	methods, para 5-6
		and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to	
		control for confounding	methods, para 5-6
		(b) Describe any methods used to examine subgroups and	
		interactions	methods, para 5-6
		(c) Explain how missing data were addressed	methods, para 5-6
		(d) If applicable, explain how loss to follow-up was addressed	n/a
		(e) Describe any sensitivity analyses	methods, para 5-6
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg	
		numbers potentially eligible, examined for eligibility,	results, para 1;
		confirmed eligible, included in the study, completing follow-	figure 1
		up, and analysed	
		(b) Give reasons for non-participation at each stage	n/a
		(c) Consider use of a flow diagram	figure 1

Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	results, para 1-2, table 1
		(b) Indicate number of participants with missing data for each variable of interest	tables as appropriate
		(c) Summarise follow-up time (eg, average and total amount)	n/a
Outcome data	15*	Report numbers of outcome events or summary measures over time	results, figures, tables
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	results, figures, tables
		(b) Report category boundaries when continuous variables were categorized	n/a
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	n/a
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	results, supplementary tables
Discussion			
Key results	18	Summarise key results with reference to study objectives	discussion, para 1
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	discussion, para 5
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	discussion
Generalisability	21	Discuss the generalisability (external validity) of the study results	discussion
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	abstract,methods, funding section

^{*}Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.